According to DelveInsight’s analysis, the Lewy body dementia market is anticipated to increase during the forecast period (2025-2034), owing to the launch of emerging therapies such as Neflamapimod (CervoMed), Zervimesine (Cognition Therapeutics), Nilotinib (KeifeRx), and others, and healthcare spending in the 7MM.
LAS VEGAS, July 10, 2025 /PRNewswire/ — Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain. This buildup leads to cognitive impairments, visual hallucinations, Parkinson-like motor symptoms, and fluctuating attention levels.
LBD encompasses two main subtypes: Dementia with Lewy bodies (DLB), where cognitive issues arise before or at the same time as motor symptoms, and Parkinson’s Disease Dementia (PDD), in which dementia appears more than a year after the onset of motor symptoms. While both share the same underlying pathology involving alpha-synuclein, they differ based on the sequence of symptom advancement.
Diagnosis is primarily clinical,supported by cognitive assessments,neuroimaging,and sleep evaluations,although definitive diagnosis is possible only post-mortem. Treatment is symptom-oriented and includes cholinesterase inhibitors, selective use of Parkinson’s medications, and interventions for psychiatric and sleep disturbances, though care must be taken not to worsen cognitive issues.
According to DelveInsight, there were around 12 million diagnosed cases of dementia across the 7MM in 2024, with expectations of significant growth through 2034, driven by a rising CAGR. According to DelveInsight’s 2024 analysis, approximately 330K diagnosed prevalent cases of DLB were reported in the US, emphasizing the significant disease burden in one of the world’s key pharmaceutical markets. This substantial patient population underlines the urgent need for improved diagnostic tools and effective treatment options within the US healthcare landscape.Download the report to understand which factors are driving Lewy body dementia epidemiology trends @ Lewy Body Dementia Treatment Algorithm
Currently, LBD has no approved disease-modifying therapies (DMTs), and existing treatments offer only partial symptomatic relief. These are often limited by side effects or may worsen certain symptoms. The complexity of managing overlapping cognitive, motor, and psychiatric issues underscores the urgent need for more effective, targeted, and better-tolerated therapies to improve quality of life for patients.
Lewy body dementia presents with a distinctive mix of cognitive, motor, and psychiatric symptoms. Existing treatments tend to address these symptoms individually and often fall short in effectiveness. There is a pressing need for therapies that target multiple symptoms simultaneously or are customized to LBD’s underlying neurobiology, offering more thorough and lasting care.
Patients with LBD are particularly vulnerable to adverse drug reactions, especially from antipsychotics, which can cause severe, even life-threatening side effects. This drug sensitivity severely limits treatment options and adds complexity to clinical management. safer,more tolerable therapies that alleviate neuropsychiatric symptoms without worsening cognition or motor function are critically needed.
Currently, there are no dependable, non-invasive biomarkers to confirm an LBD diagnosis during life. Diagnosis relies mainly on clinical presentation, which often results in misdiagnosis or delayed recognition. A validated biomarker would enhance early and accurate diagnosis,aid in identifying apprThe Lewy Body Dementia (LBD) market is expected to grow at a significant CAGR by 2034. This growth is mainly driven by increased awareness, improved diagnostic capabilities, and an aging global population. The lack of disease-modifying therapies has created a strong demand for novel treatment options. Ongoing clinical trials targeting alpha-synuclein pathology are attracting significant investment. Additionally, regulatory support is accelerating therapeutic development in this underserved neurodegenerative space.
DelveInsight’s latest published market report, titled as Lewy Body Dementia Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the Lewy body dementia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market’s underlying potential. The Lewy body dementia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
Total Diagnosed Prevalent Cases of Dementia
total Diagnosed Prevalent Cases of LBD
Gender-specific Diagnosed Prevalent Cases of LBD
Type-specific Diagnosed Prevalent Cases of LBD
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Lewy body dementia market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
industry Expert’s Opinion
* access and Reimbursement
Download this Lewy body dementia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs’ opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the Lewy body dementia market. Also, stay abreast of the mitigating factors to improve yoru market position in the Lewy body dementia therapeutic space.
Related Reports
Lewy Body Dementia Pipeline
Lewy Body Dementia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key FCS companies, including EIP Pharma Inc., Cognition Therapeutics, Eisai Inc., Sun Pharma Advanced Research Company limited, Georgetown University, Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., among others.